When comparing insider and institutional ownership, 86.5 percent of Zimmer Biomet’s shares are owned by institutional investors while 5.6 percent of Amedica shares are owned by institutional investors.
Zimmer Biomet also reported higher revenues and earnings compared to Amedica. In 2017, Zimmer Biomet reported $7.82 billion in revenues, and Amedica reported $15.23 million. The two companies also had stark differences in net income. Zimmer Biomet reported $1.81 billion while Amedica saw a $14.76 million loss in net income.
Amedica’s beta is at 1.36, suggesting its stock price is 236 percent less volatile. In comparison, Zimmer Biomet’s beta is +1.13, meaning it is 13 percent more volatile.
In all, Zimmer Biomet beat Amedica on 13 of 16 factors used to compare the companies.
More articles on devices and implants:
OrthoPediatrics introduces upgraded elastic nailing platform PediFlex Advanced: 4 insights
K2M, Smith & Nephew & more: 5 device company launches, releases
5 things to know about Xenco Medical CEO Jason Haider
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.
